Sign In
RETA.US

Reata Pharmaceuticals (RETA) $45M Shareholder Settlement

E.D. Texas
Court
4:21-cv-00987
Case number
14 Nov 2016
Class period Start
08 Dec 2021
Class period End
24 Apr 2024
Claim deadline
Reata Pharmaceuticals (RETA) agreed to settle $45 million with shareholders to end claims over failing to disclose concerns about the validity of a clinical study for kidney disease candidate, bardoxolone.
  • Reata supposedly didn't disclose FDA concerns about the validity of a clinical study for kidney disease treatment, causing a $RETA fall.
  • Reata agreed to pay $45M to investors to resolve the claims due to this case.
Reata Pharmaceuticals developed a drug called bardoxolone for kidney disease. They applied for FDA approval, highlighting positive study results.

However, Reata supposedly didn't reveal FDA concerns about the study's validity, risking the drug's approval.

On December 6, 2021, the FDA questioned the study design, causing $RETA to drop by 38%.

Two days later, the FDA declared bardoxolone ineffective, leading to an additional 46% $RETA decline.

Reata has now decided to resolve all the allegations and pay a $45M settlement.
Alleged Offence
Mismanagement
Misleading Statements
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
1.67
Filing date
20 December 2021
Lead Plaintiff Deadline
18 February 2022
Plaintiffs
Tim Doyle
Attorneys
Kirby McInerney LLP
Defendants
Warren Huff, Manmeet S. Soni, Colin J. Meyer, R. Kent McGaughy, Jr., Jack B. Nielsen, William E.Rose, William D. McClellan, Jr., and James E. Bass
Judge
Amos L. Mazzant III
Administrator
EPIQ
Class wide damages
$834,300,000
Trades matching type
LIFO
+$45,000,000
Total Settlement Amount
Created by Polina Foster, Scout

Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The comp...

    Ticker
    RETA.US
    ISIN
    US75615P1030
    CIK
    1358762
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    5320 Legacy Drive, Plano, TX, United States, 75024